Market capitalization | $193.70m |
Enterprise Value | $70.30m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 0.67 |
P/S ratio (TTM) P/S ratio | 1.84 |
P/B ratio (TTM) P/B ratio | 3.58 |
Revenue (TTM) Revenue | $105.32m |
EBIT (operating result TTM) EBIT | $-62.82m |
Cash position | $327.03m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Gossamer Bio, Inc. forecast:
8 Analysts have issued a Gossamer Bio, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 105 105 |
-
|
|
Gross Profit | 101 101 |
2,340%
2,340%
|
|
EBITDA | -59 -59 |
68%
68%
|
EBIT (Operating Income) EBIT | -63 -63 |
67%
67%
|
Net Profit | -72 -72 |
62%
62%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Faheem Hasnain |
Employees | 135 |
Founded | 2015 |
Website | www.gossamerbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.